Buy & Sell Harmony Gold Mining Co. (HMY) – Harmony Gold Mining Co. Price Today
Aura AI Summary
Key Stats
- $11.40BMarket Cap
- Basic MaterialsSector
- -40.91%3M Drawdown
- $11.74BEnterprise Value
- 2.23%Dividend Yield
- 19% Buy | 81% SellTrading Activity
- 38 daysTypical Hold Time
Harmony Gold Mining Co. (HMY) is currently valued at a market capitalization of $11.40B, with an enterprise value of $11.74B. Over the past 52 weeks, Harmony Gold Mining Co. has traded between a low of $12.61 and a high of $26.04, highlighting its annual price range. Over the past three months, Harmony Gold Mining Co. has recorded a drawdown of -40.91%, reflecting recent price volatility. Harmony Gold Mining Co. offers a dividend yield of 2.23%, with the most recent dividend of $0.31 paid on 24 Apr 26. On average, investors hold Harmony Gold Mining Co. for approximately 38 days, indicating typical investor behavior on the platform.
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Most Recent News
ExxonMobil warns oil prices could spike to $160/barrel amid low inventories and geopolitical tensions.
ExxonMobil's Senior Vice President Neil Chapman warned that crude oil prices could surge to $150-$160 per barrel soon due to critically low inventory levels, despite recent price drops linked to U.S.-Iran peace talks. The company highlighted that str...

XRP shows signs of bottoming as smart money accumulates and ETFs hit best month of 2026.
XRP has shown signs of bottoming after a five-month consolidation, with smart money investors increasing accumulation. XRP ETFs recorded their best month in 2026, adding $131 million in inflows in May, contrasting with declines in Bitcoin and Ethereu...

Whitehawk reveals SEZ6 as a promising target for new cancer drug HWK-206, advancing to clinical trials in 2026.
Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody dru...
